159 related articles for article (PubMed ID: 15517324)
1. Patients with a large prostate show a higher prevalence of androgenetic alopecia.
Chen W; Yang CC; Chen GY; Wu MC; Sheu HM; Tzai TS
Arch Dermatol Res; 2004 Nov; 296(6):245-9. PubMed ID: 15517324
[TBL] [Abstract][Full Text] [Related]
2. [A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia].
Xu J; Qian WQ; Song JD
Zhonghua Nan Ke Xue; 2008 Jun; 14(6):533-7. PubMed ID: 18649754
[TBL] [Abstract][Full Text] [Related]
3. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
4. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
Te AE; Malloy TR; Stein BS; Ulchaker JC; Nseyo UO; Hai MA
BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717
[TBL] [Abstract][Full Text] [Related]
5. Men with Kennedy disease have a reduced risk of androgenetic alopecia.
Sinclair R; Greenland KJ; Egmond Sv; Hoedemaker C; Chapman A; Zajac JD
Br J Dermatol; 2007 Aug; 157(2):290-4. PubMed ID: 17596176
[TBL] [Abstract][Full Text] [Related]
6. Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old.
Camacho FM; García-Hernández MJ; Fernández-Crehuet JL
Br J Dermatol; 2008 May; 158(5):1121-4. PubMed ID: 18363752
[TBL] [Abstract][Full Text] [Related]
7. [Association study between benign prostatic hyperplasia and primary hypertension].
Guo LJ; Zhang XH; Li PJ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Jan; 43(2):108-11. PubMed ID: 15771818
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
Kaplan SA; McConnell JD; Roehrborn CG; Meehan AG; Lee MW; Noble WR; Kusek JW; Nyberg LM;
J Urol; 2006 Jan; 175(1):217-20; discussion 220-1. PubMed ID: 16406915
[TBL] [Abstract][Full Text] [Related]
9. Baldness, benign prostate hyperplasia, prostate cancer and androgen levels.
Faydaci G; Bilal E; Necmettin P; Fatih T; Asuman O; Uğur K
Aging Male; 2008 Dec; 11(4):189-92. PubMed ID: 19172550
[TBL] [Abstract][Full Text] [Related]
10. Androgenetic alopecia and insulin resistance in young men.
González-González JG; Mancillas-Adame LG; Fernández-Reyes M; Gómez-Flores M; Lavalle-González FJ; Ocampo-Candiani J; Villarreal-Pérez JZ
Clin Endocrinol (Oxf); 2009 Oct; 71(4):494-9. PubMed ID: 19094069
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
[TBL] [Abstract][Full Text] [Related]
12. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men.
Liu CC; Huang SP; Li WM; Wang CJ; Chou YH; Li CC; Huang CH; Wu WJ
Urology; 2007 Oct; 70(4):677-80. PubMed ID: 17991536
[TBL] [Abstract][Full Text] [Related]
13. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
Vela-Navarrete R; Gonzalez-Enguita C; Garcia-Cardoso JV; Manzarbeitia F; Sarasa-Corral JL; Granizo JJ
BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526
[TBL] [Abstract][Full Text] [Related]
14. Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease?
Berger AP; Horninger W; Bektic J; Pelzer A; Spranger R; Bartsch G; Frauscher F
BJU Int; 2006 Sep; 98(3):587-90. PubMed ID: 16796699
[TBL] [Abstract][Full Text] [Related]
15. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial.
Colli E; Rigatti P; Montorsi F; Artibani W; Petta S; Mondaini N; Scarpa R; Usai P; Olivieri L; Maggi M;
Eur Urol; 2006 Jan; 49(1):82-6. PubMed ID: 16310924
[TBL] [Abstract][Full Text] [Related]
16. Male pattern androgenetic alopecia in an Indian context: a perspective study.
Sehgal VN; Kak R; Aggarwal A; Srivastava G; Rajput P
J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):473-9. PubMed ID: 17373973
[TBL] [Abstract][Full Text] [Related]
17. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
Marks LS; Roehrborn CG; Wolford E; Wilson TH
J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
[TBL] [Abstract][Full Text] [Related]
18. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia.
Ozden C; Ozdal OL; Urgancioglu G; Koyuncu H; Gokkaya S; Memis A
Eur Urol; 2007 Jan; 51(1):199-203; discussion 204-6. PubMed ID: 16806666
[TBL] [Abstract][Full Text] [Related]
19. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
[TBL] [Abstract][Full Text] [Related]
20. [Experimental research on spontaneous benign prostatic hyperplasia in old dogs].
Cai RF; Cui YG; Hua LX; Jia Y; Ma DZ; Wang XH
Zhonghua Nan Ke Xue; 2003 Dec; 9(9):651-3, 657. PubMed ID: 14727348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
